Palliser Capital UK Ltd Buys New Stake in Becton, Dickinson and Company $BDX

Palliser Capital UK Ltd purchased a new position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 13,533 shares of the medical instruments supplier's stock, valued at approximately $2,048,000. Becton, Dickinson and Company makes up about 1.1% of Palliser Capital UK Ltd's holdings, making the stock its 14th largest holding.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Manning & Napier Advisors LLC increased its holdings in Becton, Dickinson and Company by 10.5% in the second quarter. Manning & Napier Advisors LLC now owns 34,426 shares of the medical instruments supplier's stock valued at $5,343,000 after buying an additional 3,278 shares in the last quarter. Vega Investment Solutions purchased a new stake in shares of Becton, Dickinson and Company during the 2nd quarter worth about $182,000. Aberdeen Wealth Management LLC acquired a new stake in shares of Becton, Dickinson and Company during the 2nd quarter valued at about $44,000. Cullen Capital Management LLC grew its position in shares of Becton, Dickinson and Company by 13.1% during the 2nd quarter. Cullen Capital Management LLC now owns 824,720 shares of the medical instruments supplier's stock valued at $124,805,000 after acquiring an additional 95,559 shares during the period. Finally, Allstate Corp increased its stake in shares of Becton, Dickinson and Company by 4.8% in the 2nd quarter. Allstate Corp now owns 36,187 shares of the medical instruments supplier's stock valued at $5,476,000 after purchasing an additional 1,654 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company's stock.

Analysts Set New Price Targets

BDX has been the topic of a number of recent analyst reports. Barclays increased their price target on Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an "overweight" rating in a research report on Monday, May 11th. TD Cowen boosted their price objective on Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a "hold" rating in a research report on Wednesday, August 5th. Wells Fargo & Company upped their target price on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an "equal weight" rating in a research note on Friday, August 7th. UBS Group began coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, July 28th. They issued a "buy" rating and a $190.00 price target on the stock. Finally, Stifel Nicolaus set a $195.00 price target on shares of Becton, Dickinson and Company in a report on Friday, August 7th. Eight investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Becton, Dickinson and Company currently has an average rating of "Hold" and a consensus price target of $185.67.

Insider Buying and Selling

In other news, EVP Michael David Garrison sold 1,100 shares of the stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the completion of the sale, the executive vice president owned 13,172 shares of the company's stock, valued at $1,918,633.52. This represents a 7.71% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of the firm's stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the sale, the chief executive officer owned 110,163 shares of the company's stock, valued at $20,380,155. This represents a 3.63% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 11,704 shares of company stock worth $1,963,618. Insiders own 0.40% of the company's stock.

Becton, Dickinson and Company Price Performance

NYSE:BDX opened at $190.58 on Tuesday. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $193.07. The stock has a market cap of $52.51 billion, a PE ratio of 57.40, a P/E/G ratio of 13.53 and a beta of 0.19. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. The stock has a 50 day moving average price of $162.48 and a 200 day moving average price of $160.73.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping analysts' consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The company had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same quarter in the previous year, the company posted $3.68 earnings per share. The firm's revenue for the quarter was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities research analysts expect that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be issued a $1.05 dividend. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.2%. Becton, Dickinson and Company's dividend payout ratio is currently 126.51%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source